Small cell carcinoma of the ovary

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:370396C56
Who is this for?
Show terms as
2FDA treatments8Active trials23Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Small cell carcinoma of the ovary (SCCO), also known as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive form of ovarian cancer. It most commonly affects young women and adolescents, with the average age at diagnosis being around 24 years old. Despite its name, it is not related to small cell lung cancer. This cancer is now understood to be driven by mutations in a gene called SMARCA4, which normally helps control cell growth. The disease typically presents as a rapidly growing mass in one ovary. One of its hallmark features is high calcium levels in the blood (hypercalcemia), which occurs in about two-thirds of patients and can cause symptoms like excessive thirst, frequent urination, nausea, confusion, and fatigue. Patients often experience abdominal pain, bloating, and a feeling of fullness. The tumor tends to grow quickly and can spread to other parts of the body. Treatment usually involves a combination of surgery to remove the tumor, followed by intensive chemotherapy and sometimes radiation therapy. Because this cancer is so rare and aggressive, there is no single standard treatment protocol that is universally agreed upon. High-dose chemotherapy with stem cell rescue has been used in some cases. Despite treatment, the prognosis has historically been poor, especially for advanced-stage disease, though outcomes are improving with more aggressive multi-modal treatment approaches and emerging targeted therapies. Clinical trials are actively exploring new treatment options, including immune checkpoint inhibitors and drugs targeting the underlying genetic defect.

Also known as:

Key symptoms:

Abdominal pain or pelvic painAbdominal bloating or swellingFeeling full quickly when eatingHigh calcium levels in the bloodExcessive thirstFrequent urinationNausea or vomitingFatigue and weaknessUnexplained weight lossConstipationConfusion or mental fogginess from high calciumA mass or lump felt in the abdomenIrregular menstrual periods

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Juvenile

Begins in the teen years

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Conjupro Biotherapeutics, Inc. — PHASE1

TrialRECRUITING
Dec 2025Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Whitehawk Therapeutics, Inc. — PHASE1

TrialRECRUITING
Dec 2025Minimal Residual Disease in Solid Malignancies

European Institute of Oncology — NA

TrialNOT YET RECRUITING
Jan 2025Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

AstraZeneca — PHASE1

TrialNOT YET RECRUITING
Jan 2025A Phase 1 Study of LNCB74 in Advanced Solid Tumors

NextCure, Inc. — PHASE1

TrialRECRUITING
Sep 2024A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

Heronova Pharmaceuticals — PHASE1, PHASE2

TrialRECRUITING
May 2024Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Cancer Institute (NCI) — PHASE1

TrialACTIVE NOT RECRUITING
Nov 2023A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen, a wholly owned subsidiary of Pfizer — PHASE2

TrialACTIVE NOT RECRUITING
Jan 2022A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Ascendis Pharma Oncology Division A/S — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Dec 2021GEN1047 for Solid Tumors - First in Human (FIH) Trial

Genmab — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Taxol

Paclitaxel· Bristol-Myers Squibb Pharmaceutical Research Institute■ Boxed Warning

indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary

Oncoscint CR/OV

Satumomab pendetide· Cytogen CorporationOrphan Drug

For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.

Clinical Trials

8 recruitingView all trials with filters →
Phase 21 trial
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Phase 2
Actively Recruiting
PI: Patricia PAUTIER, MD, PhD (Gustave Roussy, Cancer Campus, Grand Paris) · Sites: Angers; Angers +11 more · Age: 1299 yrs
Phase 15 trials
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Phase 1
Actively Recruiting
PI: Margaret C Dugan, MD (Whitehawk Therapeutics) · Sites: Little Rock, Arkansas; Los Angeles, California +10 more · Age: 1899 yrs
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Phase 1
Actively Recruiting
· Sites: Newport Beach, California; Edgewood, Kentucky +12 more · Age: 1899 yrs
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Phase 1
Active
PI: Steven A Rosenberg, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1872 yrs
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1
Actively Recruiting
· Sites: Plantation, Florida; Plantation, Florida +3 more · Age: 1899 yrs
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
Phase 1
Actively Recruiting
· Sites: London, London; London +2 more · Age: 1875 yrs

Specialists

23 foundView all specialists →
WM
Willis Navarro, MD
TUCSON, AZ
Specialist
PI on 4 active trials
PM
Paul Martin
Specialist
PI on 3 active trials73 Small cell carcinoma of the ovary publications
SM
Susan K. Parsons, MD, MRP
Specialist
PI on 1 active trial
SM
Shivaani Kummar, MD
PORTLAND, OR
Specialist
PI on 5 active trials
NM
Nagla Karim, MD
Specialist
PI on 1 active trial
GM
Glen Liu, M.D
Specialist
PI on 1 active trial
TY
Timothy Yap
HOUSTON, TX
Specialist
PI on 1 active trial13 Small cell carcinoma of the ovary publications
LH
Lily Hu
TAUNTON, MA
Specialist
PI on 3 active trials158 Small cell carcinoma of the ovary publications
AM
Ana Oaknin, MD
Specialist
PI on 1 active trial1 Small cell carcinoma of the ovary publication
RM
Robert Burger, MD
Specialist
PI on 5 active trials
JD
Javier Toledo, Medical Degree
Specialist
PI on 1 active trial2 Small cell carcinoma of the ovary publications
CM
Charlotte Proby, MBBS,FRCP
Specialist
PI on 1 active trial
JD
Joohang Kim, Dr
Specialist
PI on 1 active trial
MJ
Melissa Johnson
Specialist
PI on 2 active trials
SD
Susan Domchek
PHILADELPHIA, PA
Specialist
PI on 1 active trial
JY
John J You
HOUSTON, TX
Specialist
PI on 1 active trial
AS
Ashish Sangal
WEST ISLIP, NY
Specialist
PI on 1 active trial
MD
Margaret C Dugan
NORWALK, IA
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Taxol(Paclitaxel)Bristol-Myers Squibb Pharmaceutical Research Institute

Travel Grants

No travel grants are currently matched to Small cell carcinoma of the ovary.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Small cell carcinoma of the ovaryForum →

No community posts yet. Be the first to share your experience with Small cell carcinoma of the ovary.

Start the conversation →

Latest news about Small cell carcinoma of the ovary

Disease timeline:

New recruiting trial: A Phase 1 Study of LNCB74 in Advanced Solid Tumors

A new clinical trial is recruiting patients for Small cell carcinoma of the ovary

New recruiting trial: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

A new clinical trial is recruiting patients for Small cell carcinoma of the ovary

New recruiting trial: Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

A new clinical trial is recruiting patients for Small cell carcinoma of the ovary

New recruiting trial: A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

A new clinical trial is recruiting patients for Small cell carcinoma of the ovary

New recruiting trial: First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

A new clinical trial is recruiting patients for Small cell carcinoma of the ovary

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my cancer, and has it spread beyond the ovary?,Should I have genetic testing for SMARCA4, and what would the results mean for my family?,What are my options for preserving fertility before treatment begins?,What treatment plan do you recommend, and is high-dose chemotherapy with stem cell transplant an option for me?,Are there any clinical trials I should consider, and how do I access them?,Should I be treated at a specialized center with experience in this rare cancer?,What is my expected prognosis, and what follow-up monitoring will I need after treatment?

Common questions about Small cell carcinoma of the ovary

What is Small cell carcinoma of the ovary?

Small cell carcinoma of the ovary (SCCO), also known as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive form of ovarian cancer. It most commonly affects young women and adolescents, with the average age at diagnosis being around 24 years old. Despite its name, it is not related to small cell lung cancer. This cancer is now understood to be driven by mutations in a gene called SMARCA4, which normally helps control cell growth. The disease typically presents as a rapidly growing mass in one ovary. One of its hallmark features is high calcium l

At what age does Small cell carcinoma of the ovary typically begin?

Typical onset of Small cell carcinoma of the ovary is juvenile. Age of onset can vary across affected individuals.

Are there clinical trials for Small cell carcinoma of the ovary?

Yes — 8 recruiting clinical trials are currently listed for Small cell carcinoma of the ovary on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Small cell carcinoma of the ovary?

23 specialists and care centers treating Small cell carcinoma of the ovary are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Small cell carcinoma of the ovary?

2 patient support programs are currently tracked on UniteRare for Small cell carcinoma of the ovary. See the treatments and support programs sections for copay assistance, eligibility, and contact details.